WuXi Biologics' ADC Drug CMO Business Backlog Reaches USD 1.33 Billion

Based on the latest information I have obtained, details regarding the backlog of WuXi Biologics (HK02269) ADC Drug CMO Business are as follows:

• WuXi XDC is an ADC/XDC bioconjugate drug CRDMO platform jointly established by WuXi Biologics (02269.HK) and WuXi AppTec via its subsidiary WuXi STA
• Based on revenue, it is
  the world’s second-largest CRDMO for ADC and other bioconjugate drugs
  , with its market share increasing from 9.9% in 2022 to 22-24% in 2025[1][3]

• Over
  630 collaborative clients worldwide
• Total number of iCMC projects:
  252
• Including
  18 PPQ (Process Performance Qualification) projects
  and
  1 commercial-scale project
• Total number of integrated projects reaches
  225
  [1][2]

• Phase III clinical projects:
  23
• Commercial production projects:
  1
• ADC projects account for
  33%
  of WuXi Biologics’ total projects (945 in total), representing a year-on-year increase of
  30%
  [4]

• Revenue:
  RMB 2.7 billion
  , with a year-on-year growth of
  62.2%
• Net profit attributable to parent company:
  RMB 746 million
  , with a year-on-year growth of
  52.74%
• Gross profit margin: Over
  70%
  [1][2]

WuXi XDC recently announced the acquisition of Shanghai Topscience Pharma for

[1] PharnexCloud - WuXi XDC Acquires Shanghai Topscience Pharma with 99% Premium! Capacity Expansion + Ecological Positioning (https://www.pharnexcloud.com/zixun/sx_267871)

[2] Sina Finance - WuXi XDC, Leading ADC Outsourcing Provider, Acquires Shanghai Topscience Pharma with Over 100% Premium to “Race Against Time” (https://finance.sina.com.cn/jjxw/2026-01-16/doc-inhhnzaw0684693.shtml)

[3] Pharmcube ByDrug - HKD 3.091 Billion: China’s Top ADC CDMO Makes Another Acquisition (https://bydrug.pharmcube.com/news/detail/4b6c8a9370e413a26df1896bd5a0947c)

[4] Gelonghui - WuXi Biologics Unleashes Stunning M-Segment Volume Growth; WuXi AppTec Earned Over RMB 13 Billion in Net Profit Last Year! (https://news.qq.com/rain/a/20260113A01IMM00)